In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 661 ( 2022-09-07)
Abstract:
Antiviral therapeutics have become an essential component of the response to the COVID-19 pandemic. However, the antiviral treatment remdesivir requires intravenous administration, limiting its clinical utility. Here, Cao et al. developed 24 modified versions of the parent nucleoside of remdesivir, GS-441524, to identify a version with qualities favorable to oral administration. The authors found that one candidate, ATV006, was orally bioavailable. Further, ATV006 was effective at reducing viral load and disease severity in three preclinical models of SARS-CoV-2 infection. Together, these results support further development of ATV006 and other similar antiviral drug candidates.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abm7621
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Permalink